-
Signature
-
Jan De Witte, director
-
Issuer symbol
-
RMD
-
Transactions as of
-
11 Nov 2025
-
Net transactions value
-
-$140,992
-
Form type
-
4
-
Filing time
-
13 Nov 2025, 17:24:31 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| De Witte Jan |
Director |
9001 SPECTRUM CENTER BLVD., C/O RESMED INC, SAN DIEGO |
Jan De Witte, director |
13 Nov 2025 |
0001776929 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RMD |
ReMed Common Stock |
Sale |
$121,872 |
-487 |
-8.4% |
$250.25 |
5,319 |
11 Nov 2025 |
Direct |
F1 |
| transaction |
RMD |
ReMed Common Stock |
Tax liability |
$19,120 |
-76 |
-1.4% |
$250.10 |
5,242 |
11 Nov 2025 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: